Ancobon (flucytosine) NDC 0187-3554

NDC codes

FDA NDC Directory

Product NDC (as listed)0187-3554Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00187-3554Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0187-3554-10	00187355410	100 CAPSULE in 1 BOTTLE (0187-3554-10)Marketed from Nov 26, 1971

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ancobon
Generic name (nonproprietary): flucytosine
Active ingredients: Flucytosine — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Bausch Health US LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 017001
Marketing start: Nov 26, 1971
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Analog (EXT)
Identifiers: Product ID 0187-3554_2611b6d9-1f11-4c1d-a2b6-ae818d39d299SPL ID 2611b6d9-1f11-4c1d-a2b6-ae818d39d299SPL set ID aea0df00-a88c-4a16-abcf-750f3ff2004eRxCUI 197702, 197703, 207125, 207127UNII D83282DT06UPC 0301873554103, 0301873555100
Pharmacologic class: Nucleoside Analog Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400187355410 followed by a unit qualifier and the quantity

Package 00187-3554-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 2, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE ANCOBON is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. ANCOBON should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to ANCOBON (see MICROBIO…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)